TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 20 or more at the time when they give consent.~* Diagnosed as malignant disease.~* Be naive to chemotherapy or have been treated with single administration of anti-tumor drugs which are classified as low emetogenicity in the first edition of the 2006 NCCN Clinical Practice Guidelines.~* Cisplatin ≥50 mg/m2 Doxorubicin + cyclophosphamide: AC Epirubicin + cyclophosphamide: EC~* WBC ≥ 3000 /mm3 AST \< 100 IU/L ALT \< 100 IU/L Creatinine clearance ≥ 60 mL/min~* Performance Status : 0 - 2~Exclusion Criteria:~* Severe (requiring hospitalization) and uncontrollable complications.~* Metastases to the brain which are symptomatic.~* Seizure disorder requiring anticonvulsant medication unless clinically stable and free of seizure activity.~* Symptomatic and invasive procedure indicated ascites or pleural effusion.~* Have either gastric outlet stenosis or intestinal obstruction.~* Have ongoing emesis or CTCAE grade 2 or greater nausea.~* QTc \> 470 msec in the 12-lead ECG within eight days before registration.~* Known anaphylactic to ingredients of the study drug, namely palonosetron or granisetron hydrochloride injection, or other 5-HT3 receptor antagonists.~* Known anaphylactic to ingredients of dexamethasone.~* Pregnant women, breast-feeding women, or any male or female who are not willing to practice adequate contraception during the study period.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): palonosetron
- 2 (Type: ACTIVE_COMPARATOR): granisetron hydrochloride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL at screening~* Chronic genotype 3 HCV infection (≥ 6 months)~* Presence of cirrhosis~* HCV treatment naive or treatment experienced with an interferon (IFN)-based regimen~* Use of protocol specified methods of contraception~Key Exclusion Criteria:~* Current or prior history of clinically significant illness that may interfere with participation in the study~* Screening ECG with clinically significant abnormalities~* Laboratory parameters outside the acceptable range at screening~* Pregnant or nursing female~* Chronic liver disease not caused by HCV~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL/VOX (Type: EXPERIMENTAL): SOF/VEL/VOX tablet for 8 weeks
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL tablet for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥18 years~* Willing and able to comply with all study requirements, including scheduled visits, interventions, and laboratory tests~* Healthy adults or adults in a stable medical condition, defined as not being hospitalized within 3 months prior to the screening visit~* Females must not be pregnant or breastfeeding~Exclusion Criteria:~* Subjects with signs of active SARS-COV-2 infection at the screening visit.~* Subjects with body temperature of 38 degrees Celsius or greater at the screening visit or within 72 hours prior to the screening visit.~* Subjects with a history of any progressive or severe neurological disorders, seizure, or Guillain-Barre syndrome.~* Subjects who receive immunosuppressive or cytotoxic medications.~* Female Subjects who are pregnant or breastfeeding or have planned to become pregnant during the study period.~* Subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products.~* Subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study.~* Subjects who have been vaccinated with any vaccine or vaccine candidate against SARS-CoV-2.~* Subjects who have received any vaccines within 28 days prior to the screening visit or intend to receive any vaccines up to 14 days after the second dose of the study injection.~* Subjects who have any known bleeding disorders or, in the investigator's opinion, have any contraindications for an intramuscular injection.~* Subjects who have received any blood, plasma, or immunoglobulin products from 90 days prior to the screening visit or intend to receive during the study period.~* Subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion.~* Subjects who have donated ≥450 mL of blood or blood products within 28 days prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vaccine candidate (Type: EXPERIMENTAL): None
- Saline placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. You must be at least 18 years old~2. You must have been diagnosed with non-squamous non-small cell lung cancer (NSCLC)~3. You must have had no prior systemic anticancer therapy for lung cancer~4. You must live close enough to the study doctor to be able to visit regularly for follow up~5. You must have signed informed consent form indicating your willingness to take part in this study~6. Your laboratory and medical history and tests must meet study requirements~Exclusion criteria:~1. Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry~2. Prior radiotherapy and surgery should be completed at least 4 weeks prior to initiation of treatment~3. Serious concomitant systemic disorder (e.g., active infection including human immunodeficiency virus, or unstable cardiovascular disease)~4. Prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer unless treated at least 5 years previously with no subsequent evidence of recurrence~5. Brain metastasis~6. Presence of clinically significant (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry~7. Significant weight loss (greater than 10%), over the previous 6 weeks before study entry~8. Concurrent administration of any other antitumor therapy~9. Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam)~10. Inability or unwillingness to take folic acid, dexamethasone (or equivalent) or vitamin B12 supplementation~11. Pregnancy or breast-feeding~12. You are allergic to pemetrexed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Pemetrexed + Best Supportive Care (Type: EXPERIMENTAL): Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles~Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
- B: Best Supportive Care (Type: ACTIVE_COMPARATOR): Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Recruited subjects include all adult patients ≥18 years hospitalised for virologically confirmed 2019-n-CoV infection.~2. NEWS of ≥1 upon recruitment~3. Auditory temperature ≥38°C with at least one of the following symptoms (cough, sputum production, sore-throat, nasal discharge, myalgia, headache or fatigue) upon admission~4. Symptom duration ≤10 days~5. All subjects give written informed consent.~6. Subjects must be available to complete the study and comply with study procedures. Willingness to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response.~Exclusion Criteria:~1. Inability to comprehend and to follow all required study procedures.~2. Allergy or severe reactions to the study drugs~3. Patients with known prolonged QT or PR interval, second- or third-degree heart block, or ventricular cardiac arrhythmias, including torsade de pointes~4. Patients taking medication that will potentially interact with lopinavir/ ritonavir, ribavirin or interferon-beta1b~5. Patients with known history of severe depression~6. Pregnant or lactation women~7. Inability to comprehend and to follow all required study procedures~8. Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to recruitment in this study or expect to receive an experimental agent during this study. Unwilling to refuse participation in another clinical study through the end of this study.~9. Have a history of alcohol or drug abuse in the last 5 years.~10. Have any condition that the investigator believes may interfere with successful completion of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study group (Type: ACTIVE_COMPARATOR): triple combination
- Control group (Type: ACTIVE_COMPARATOR): single

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Bronchial Asthma With Borage and Echium Seed Oils

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of bronchial asthma~* Male or female 18 years to 65 years of age~* FEV1 50 to 90% of predicted, or personal best.~* Improvement of \>=12% FEV1 with bronchodilator~Exclusion Criteria:~* Pregnant or nursing~* Smoking history of \> 10 pack years or active smoking within the past year.~* Due to possible effects on leukotriene biosynthesis, use of the following asthma treatments within the preceding month will be exclusion criteria:~  * leukotriene modifying drugs,~ * theophylline~ * oral steroids.~ * dietary supplements with fatty acids or other products that may interfere with leukotriene generation.~* Treatment within the previous three months with omalizumab (monoclonal antibody directed against IgE)~* Subjects will not be permitted to take non-steroidal anti-inflammatory drugs in the week prior to any measurements of ex vivo leukotriene generation because of their effects on leukotriene biosynthesis via inhibition of prostaglandin generation.~* A history of aspirin-sensitive asthma~* Significant abnormalities in CBC, differential white cell count, renal function, and liver function, or urinalysis.~* Any serious co-morbid medical condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1: Borage Seed Oil and Echium Seed Oil (Type: EXPERIMENTAL): Borage/Echium plant seed oils: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
- 2: Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo comparator: 9 g/day corn oil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female aged 18 to 75 years, inclusive.~* Patient who has moderately to severely active CD with a score on the CDAI of 220 to 450 points~Exclusion Criteria:~* Patient who has previously received either a TNFα inhibitor or biological agent within 5 half-lives~* Patient who has previously demonstrated inadequate response or intolerance to TNFα inhibitors for the treatment of CD.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CT-P13 SC (Type: EXPERIMENTAL): None
- Placebo SC (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Emails Promoting COVID-19 Vaccination Among Healthcare Workers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Employees at Geisinger Health System who have not gotten a COVID-19 vaccination~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Delayed Contact (Type: NO_INTERVENTION): This group will not receive an email for at least two days.
- Social Proof (Type: EXPERIMENTAL): This group will receive an email that points out that vaccine availability for employees will soon be limited. It also emphasizes how many fellow health care workers have been vaccinated. Seeing the behaviors of other people might encourage recipients to copy that behavior.
- Reframing Side Effects and Adverse Reactions (Type: EXPERIMENTAL): This group will receive an email that points out that vaccine availability for employees will soon be limited. It also addresses concerns about the side effects and adverse reactions of the vaccine. Due to potentially overblown concerns about the vaccine caused by the salience of side effects in the (social) media, the email attempts to reframe the risks by explicitly noting the small possibility of being affected by serious side effects and by contrasting that to the more severe effects of COVID-19. As a result of this reframing, recipients might recalibrate their perception of risks and benefits and opt for vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has an HbA1c value \<=11.0%~* The subject has a body mass index (BMI) of 25 kg/m\^2 to 45 kg/m\^2, inclusive~Exclusion Criteria:~* Is currently treated with certain medications, including exogenous insulin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): Exenatide 5 mcg for 4 weeks (transition) then 10 mcg to study termination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human Prolactin for Lactation Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women, aged 18-45 years~* Lactation insufficiency postpartum~* Subjects will be women with children in the neonatal Intensive Care Unit (ICU) who are pumping breast milk for their infant's nutritional support and to maintain their milk supply.~* Subjects will have given birth at a gestational age of at least 24 weeks, and will generally be recruited 4-8 weeks postpartum.~Exclusion Criteria:~* Medications known to increase prolactin~* Anatomical breast abnormalities~* Use of medication contraindicated in breastfeeding mothers~* Allergies to mannitol~* Current use of hormonal contraception~* Previous mammoplasty or breast augmentation, unless they have successfully nursed an infant for 3 months in the past without requiring supplemental formula.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Placebo group normal saline twice per day
- 2 (Type: ACTIVE_COMPARATOR): Recombinant human prolactin 60 mcg/kg every 12 hours
- 3 (Type: ACTIVE_COMPARATOR): Recombinant human prolactin 60 mcg/kg alternating with normal saline placebo every 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Screening plasma HIV-1 RNA ≥1000 c/mL~* Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection)~* Ability to understand and sign a written informed consent form~* Willingness to use approved methods of contraception to avoid pregnancy (women of child bearing potential only)~* Age equal to or greater than 18 years~* A negative HLAB\*5701 allele assessment~Exclusion Criteria:~* Women who are pregnant or breastfeeding;~* Active Center for Disease and Prevention Control (CDC) Category C disease~* Hepatic impairment~* HBV co-infection~* Anticipated need for HCV therapy during the study~* Allergy or intolerance to the study drugs or their components or drugs of their class~* Malignancy within the past 5 years~* Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening~* Treatment with radiation therapy, cytotoxic chemotherapeutic agents or any immunomodulator within 28 days of Screening~* Exposure to an agent with documented activity against HIV-1 in vitro or an experimental vaccine or drug within 28 days of first dose of study medication~* Primary viral resistance in the Screening result~* Verified Grade 4 laboratory abnormality~* ALT \>5 xULN~* ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with \>35% direct bilirubin);~* Estimated creatinine clearance \<50 mL/min~* Recent history (≤3 months) of upper or lower gastrointestinal bleed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dolutegravir (N=~394): (Type: EXPERIMENTAL): Dolutegravir 50mg once daily + abacavir/lamivudine as the fixed-dose combination once daily + Atripla placebo once daily
- Atripla (N=~394): (Type: ACTIVE_COMPARATOR): Atripla once daily + Dolutegravir placebo once daily + abacavir/lamivudine as the fixed-dose combination placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Palatal Brushing on Denture Stomatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health.~* Completely edentulous maxilla.~* Currently wearing complete upper dentures.~* A clinical diagnosis of denture stomatitis.~Exclusion Criteria:~* Conditions known to promote Candida carriage such as diabetes, anemia, xerostomia, immunosuppression, chemotherapy and radiotherapy.~* Use of antibiotics, antifungal agents or corticosteroids at least 4 weeks before the study.~* Previous palatal brushing habit.~* Changing of the existing prosthesis during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palatal brushing (Type: EXPERIMENTAL): Palatal brushing after each meal for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete